Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Post by Biofinderon Aug 08, 2018 10:14am

200 Views

Post# 28426592

FDA IVIG Trial

https://clinicaltrials.gov/ct2/show/NCT02269163

A Phase 3, Multinational, Multicenter, Open-Label Study of ProMetic BioTherapeutics IVIG (IGIV)

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	75 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Phase 3, Multinational, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% in Adults and Children With PID
Actual Study Start Date :	January 26, 2016
Estimated Primary Completion Date :	March 2018
Estimated Study Completion Date :	May 2018